Tower Research Capital (TRC)’s Interpace Biosciences, Inc. Common Stock IDXG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-177
| Closed | -$1K | – | 6341 |
|
|
2021
Q1 | $1K | Sell |
177
-1,752
| -91% | -$7.72K | ﹤0.01% | 5345 |
|
|
2020
Q4 | $6K | Buy |
+1,929
| New | +$6.34K | ﹤0.01% | 4595 |
|
|
2020
Q3 | – | Sell |
-1,404
| Closed | -$7K | – | 5354 |
|
|
2020
Q2 | $7K | Buy |
+1,404
| New | +$7.28K | ﹤0.01% | 4190 |
|
|
2017
Q4 | – | Sell |
-2
| Closed | – | – | 4309 |
|
|
2017
Q3 | $0 | Buy |
+2
| New | +$24 | ﹤0.01% | 4332 |
|
|
2016
Q1 | – | Sell |
-1
| Closed | – | – | 5321 |
|
|
2015
Q4 | $0 | Buy |
+1
| New | +$111 | ﹤0.01% | 5352 |
|
|
2015
Q2 | – | Sell |
-4
| Closed | -$1K | – | 5320 |
|
|
2015
Q1 | $1K | Buy |
+4
| New | +$654 | ﹤0.01% | 4218 |
|
|
2014
Q4 | – | Sell |
-4
| Closed | -$1K | – | 5011 |
|
|
2014
Q3 | $1K | Buy |
4
+2
| +100% | +$668 | ﹤0.01% | 4221 |
|
|
2014
Q2 | $1K | Sell |
2
-20
| -91% | -$9.23K | ﹤0.01% | 3830 |
|
|
2014
Q1 | $10K | Sell |
22
-55
| -71% | -$28.6K | ﹤0.01% | 2636 |
|
|
2013
Q4 | $37K | Buy |
77
+64
| +492% | +$31.3K | 0.01% | 1671 |
|
|
2013
Q3 | $6K | Sell |
13
-47
| -78% | -$22.5K | ﹤0.01% | 3592 |
|
|
2013
Q2 | $28K | Buy |
+60
| New | +$27.2K | ﹤0.01% | 1412 |
|
Tower Research Capital (TRC)'s IDXG Position: Q2 2021 in Review
Tower Research Capital (TRC) sold out of Interpace Biosciences, Inc. Common Stock (IDXG) in Q2 2021, closing a stake of 177 shares — an estimated $1K sold.
Tower Research Capital (TRC) first reported a position in IDXG in Q2 2013 and held it in 12 quarters. The position peaked at $37K in Q4 2013. 0 funds tracked by Wall St. Rank hold IDXG as of Q2 2021.
- Tower Research Capital (TRC) reported no remaining Interpace Biosciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
- Tower Research Capital (TRC) sold 177 Interpace Biosciences, Inc. Common Stock shares in Q2 2021, an estimated $1K.
- Tower Research Capital (TRC) first reported a position in Interpace Biosciences, Inc. Common Stock in Q2 2013 and held it in 12 quarters.
- Tower Research Capital (TRC)'s Interpace Biosciences, Inc. Common Stock position peaked at $37K in Q4 2013.
- 0 funds tracked by Wall St. Rank held Interpace Biosciences, Inc. Common Stock as of Q2 2021.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2021, filed 16 Aug 2021.